{
  "id": 4621832,
  "title": "BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer",
  "url": "https://urgent.news/2026/08/31/beone-medicines-announces-new-phase-3-survival-data-reinforcing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T10:05:23.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-announces-new-phase-3-survival-data-reinforcing-benefit-of-ziihera-containing-regimens-in-first-line-her2-gastroesophageal-cancer"
  },
  "original_language": "en",
  "account": null,
  "summary": "Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}